Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML
Shattuck Labs, Inc.
Shattuck Labs, Inc.
Hackensack Meridian Health
National Cancer Institute (NCI)
NextCure, Inc.
Novartis
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Incyte Corporation
Incyte Corporation
National Institutes of Health Clinical Center (CC)
Bristol-Myers Squibb
Amgen
Roswell Park Cancer Institute
Celgene
Thomas Jefferson University
M.D. Anderson Cancer Center
University of Michigan Rogel Cancer Center
Fred Hutchinson Cancer Center
Ensoma
Amgen
Ono Pharmaceutical Co. Ltd
IGF Oncology, LLC
Kyowa Kirin Co., Ltd.
Pfizer
Weill Medical College of Cornell University
Sumitomo Pharma America, Inc.
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Bellicum Pharmaceuticals
Rutgers, The State University of New Jersey
Amgen
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
GlaxoSmithKline
Fred Hutchinson Cancer Center
Medical College of Wisconsin
GT Biopharma, Inc.
Dana-Farber Cancer Institute
Kiadis Pharma
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
Incyte Corporation
Kiadis Pharma
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
University of Chicago
Fox Chase Cancer Center
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NYU Langone Health